A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy

A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy

Anti-CD20 treatment represents a therapeutic benefit for patients with B-cell lymphomas, although more efficient therapies are needed for refractory or relapsing patients. Among them, the combination of anti-CD20 and IL-2 that induces T cell response has been hampered by the expansion of FoxP3+ Treg...

Full description

Bibliographic Details
Main Authors: Ana Victoria Casadesús, Claire Deligne, Béré Kadjdiatou Diallo, Katya Sosa, Nathalie Josseaume, Circe Mesa, Kalet León, Tays Hernández, Jean-Luc Teillaud
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
anti-cd20
il-2
il-2 mutein
immunotherapy
lymphoma
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1770565

Similar Items

Similar Items